

Mid and South Essex NHS Foundation Trust (MSE)- Skin Cancer MDT and follow up pathway optimisation

Summary of Collaborative Working Project	The collaboration between Regeneron and MSE cancer services aims to review the current MDT process for skin cancer and the subsequent follow up pathway. The project will identify challenges / opportunities to improve the efficiency and consistency of the MDT and follow up pathway. This will be followed by supporting the implementation and review of any recommended changes.
The organisations involved	Mid and South Essex NHS Foundation Trust Basildon University Hospital Site, Nethermayne, Basildon, Essex, SS16 5NL Regeneron UK Ltd The Charter Building, Vine Street, Uxbridge, Middlesex, UB8 1JG
Objectives of the Project	- Review of current skin cancer pathway, MDT and follow up process. - Identify areas that require improved efficiency and consistency. - Develop implementation plan and resources to support implementation of changes
Expected outcomes	Patients - Reduction in delays, leading to more efficient communication to patients from the MDT, and therefore an opportunity to support patients along the process. - Earlier communication of a treatment plan, due to a more efficient MDT process. MSE - To improve the efficiencies across the MDT to enable improvements in Cancer Wait Time performance for skin cancer. - Improvements in staff satisfaction. - Share learning of the MDT streamlining and outcomes across other specialties. Regeneron - Building a collaborative working relationship with the NHS - To show evidence of expertise in project management and pathway redesign to support optimal care for patients. - Potential for improved access to treatments in line with NICE guidance which may or may not include Regeneron medicines.
Time Frame	March 2025 – December 2025